Among the 65 patients showing BAP1 mutation of Inserm series (Table S1), none had previous cutaneous or uveal melanoma, renal cell carcinoma, basal cell carcinoma, meningioma, or cholangiocarcinoma, which were recently described in a study on 181 families carrying BAP1 germline variants as the core tumor spectrum for the BAP1 tumor predisposition syndrome (Walpole et al., 2018). This evidence concerns the gene BAP1 and renal cell carcinoma.